Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flutamide for DSB induction in prostate cancer
NCT03507608Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2019
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of flutamide in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Fold-change Post Flutamide Exposure at 12 hours. Started May 2019; status: completed.
02
Drugs
flutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03507608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507608.